

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 June 2020 (04.06.2020)



(10) International Publication Number
WO 2020/108423 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 9/10 (2006.01)
C12N 15/13 (2006.01) A61P 11/00 (2006.01)
C12N 15/63 (2006.01) A61P 19/02 (2006.01)
C12P 21/08 (2006.01) A61P 35/02 (2006.01)
A61K 39/395 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/CN2019/120545

(22) International Filing Date:

25 November 2019 (25.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/117581

27 November 2018 (27.11.2018) CN

(71) Applicant: **STADSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.** [CN/CN]; Houfuyue/IP/5-918, No.36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN).

(72) Inventors: **ZHU, Pingxia**; Houfuyue/IP/5-918, No.36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN). **WU, Ran**; Houfuyue/IP/5-918, No.36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN). **ZHANG, Qingshuang**; Houfuyue/IP/5-918, No.36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN). **HUANG, Qun**; Houfuyue/IP/5-918, No.36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES SPECIFICALLY RECOGNIZING GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA AND USES THEREOF



FIG. 7

(57) Abstract: The present application provides antibodies including antigen-binding fragment thereof that specifically recognizing Granulocyte-Macrophage Colony Stimulating Factor Receptor (GM-CSFR α). Also provided are methods of making and using these antibodies.

WO 2020/108423 A1